



Primary Hyperoxaluria Drug Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-26	121	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Primary Hyperoxaluria Drug market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Primary Hyperoxaluria Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Primary Hyperoxaluria Drug is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Primary Hyperoxaluria Drug is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Primary Hyperoxaluria Drug include OxThera AB, Intellia Therapeutics Inc, Dicerna Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc and Allena Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Primary Hyperoxaluria Drug market in terms of revenue (US\$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Primary Hyperoxaluria Drug Market by Company

OxThera AB

Intellia Therapeutics Inc

Dicerna Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Allena Pharmaceuticals Inc

Primary Hyperoxaluria Drug Segment by Type

ALLN-230

ALN-GO1

DCR-PHXC

Others

Primary Hyperoxaluria Drug Segment by Application

Hospital

Clinic

Others

Primary Hyperoxaluria Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Hyperoxaluria Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Primary Hyperoxaluria Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Hyperoxaluria Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Primary Hyperoxaluria Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Primary Hyperoxaluria Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Primary Hyperoxaluria Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Primary Hyperoxaluria Drug Market Size (2021-2032)
 - 2.2.2 Global Primary Hyperoxaluria Drug Sales (2021-2032)
 - 2.2.3 Global Primary Hyperoxaluria Drug Market Average Price (2021-2032)
- 2.3 Primary Hyperoxaluria Drug by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 ALLN-230
 - 2.3.3 ALN-GO1
 - 2.3.4 DCR-PHXC
 - 2.3.5 Others
- 2.4 Primary Hyperoxaluria Drug by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Hospital
 - 2.4.3 Clinic
 - 2.4.4 Others

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Primary Hyperoxaluria Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Primary Hyperoxaluria Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Primary Hyperoxaluria Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Primary Hyperoxaluria Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Primary Hyperoxaluria Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Primary Hyperoxaluria Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Primary Hyperoxaluria Drug, Product Type & Application
- 3.8 Global Manufacturers of Primary Hyperoxaluria Drug, Established Date
- 3.9 Global Primary Hyperoxaluria Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 OxThera AB
 - 4.1.1 OxThera AB Company Information
 - 4.1.2 OxThera AB Business Overview
 - 4.1.3 OxThera AB Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.1.4 OxThera AB Primary Hyperoxaluria Drug Product Portfolio
 - 4.1.5 OxThera AB Recent Developments

4.2 Intellia Therapeutics Inc

4.2.1 Intellia Therapeutics Inc Company Information

4.2.2 Intellia Therapeutics Inc Business Overview

4.2.3 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2021-2026)

4.2.4 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Product Portfolio

4.2.5 Intellia Therapeutics Inc Recent Developments

4.3 Dicerna Pharmaceuticals Inc

4.3.1 Dicerna Pharmaceuticals Inc Company Information

4.3.2 Dicerna Pharmaceuticals Inc Business Overview

4.3.3 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2021-2026)

4.3.4 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio

4.3.5 Dicerna Pharmaceuticals Inc Recent Developments

4.4 Alnylam Pharmaceuticals Inc

4.4.1 Alnylam Pharmaceuticals Inc Company Information

4.4.2 Alnylam Pharmaceuticals Inc Business Overview

4.4.3 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2021-2026)

4.4.4 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio

4.4.5 Alnylam Pharmaceuticals Inc Recent Developments

4.5 Allena Pharmaceuticals Inc

4.5.1 Allena Pharmaceuticals Inc Company Information

4.5.2 Allena Pharmaceuticals Inc Business Overview

4.5.3 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2021-2026)

4.5.4 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio

4.5.5 Allena Pharmaceuticals Inc Recent Developments

5 Global Primary Hyperoxaluria Drug Market Scenario by Region

5.1 Global Primary Hyperoxaluria Drug Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Primary Hyperoxaluria Drug Sales by Region: 2021-2032

5.2.1 Global Primary Hyperoxaluria Drug Sales by Region: 2021-2026

5.2.2 Global Primary Hyperoxaluria Drug Sales by Region: 2027-2032

5.3 Global Primary Hyperoxaluria Drug Revenue by Region: 2021-2032

5.3.1 Global Primary Hyperoxaluria Drug Revenue by Region: 2021-2026

5.3.2 Global Primary Hyperoxaluria Drug Revenue by Region: 2027-2032

5.4 North America Primary Hyperoxaluria Drug Market Facts & Figures by Country

5.4.1 North America Primary Hyperoxaluria Drug Market Size by Country: 2021 VS 2025 VS 2032

5.4.2 North America Primary Hyperoxaluria Drug Sales by Country (2021-2032)

5.4.3 North America Primary Hyperoxaluria Drug Revenue by Country (2021-2032)

5.4.4 United States

5.4.5 Canada

5.4.6 Mexico

5.5 Europe Primary Hyperoxaluria Drug Market Facts & Figures by Country

5.5.1 Europe Primary Hyperoxaluria Drug Market Size by Country: 2021 VS 2025 VS 2032

5.5.2 Europe Primary Hyperoxaluria Drug Sales by Country (2021-2032)

5.5.3 Europe Primary Hyperoxaluria Drug Revenue by Country (2021-2032)

5.5.4 Germany

5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Russia

5.5.9 Spain

5.5.10 Netherlands

5.5.11 Switzerland

5.5.12 Sweden

5.5.13 Poland

5.6 Asia Pacific Primary Hyperoxaluria Drug Market Facts & Figures by Country

5.6.1 Asia Pacific Primary Hyperoxaluria Drug Market Size by Country: 2021 VS 2025 VS 2032

5.6.2 Asia Pacific Primary Hyperoxaluria Drug Sales by Country (2021-2032)

5.6.3 Asia Pacific Primary Hyperoxaluria Drug Revenue by Country (2021-2032)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 Taiwan

5.6.10 Southeast Asia

5.7 South America Primary Hyperoxaluria Drug Market Facts & Figures by Country

5.7.1 South America Primary Hyperoxaluria Drug Market Size by Country: 2021 VS 2025 VS 2032

5.7.2 South America Primary Hyperoxaluria Drug Sales by Country (2021-2032)

5.7.3 South America Primary Hyperoxaluria Drug Revenue by Country (2021-2032)

5.7.4 Brazil

5.7.5 Argentina

5.7.6 Chile

5.8 Middle East and Africa Primary Hyperoxaluria Drug Market Facts & Figures by Country

5.8.1 Middle East and Africa Primary Hyperoxaluria Drug Market Size by Country: 2021 VS 2025 VS 2032

5.8.2 Middle East and Africa Primary Hyperoxaluria Drug Sales by Country (2021-2032)

5.8.3 Middle East and Africa Primary Hyperoxaluria Drug Revenue by Country (2021-2032)

5.8.4 Egypt

5.8.5 South Africa

5.8.6 Israel

5.8.7 Türkiye

5.8.8 GCC Countries

6 Segment by Type

6.1 Global Primary Hyperoxaluria Drug Sales by Type (2021-2032)

6.1.1 Global Primary Hyperoxaluria Drug Sales by Type (2021-2032) & (W Units)

6.1.2 Global Primary Hyperoxaluria Drug Sales Market Share by Type (2021-2032)

6.2 Global Primary Hyperoxaluria Drug Revenue by Type (2021-2032)

6.2.1 Global Primary Hyperoxaluria Drug Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2021-2032)

6.3 Global Primary Hyperoxaluria Drug Price by Type (2021-2032)

7 Segment by Application

7.1 Global Primary Hyperoxaluria Drug Sales by Application (2021-2032)

7.1.1 Global Primary Hyperoxaluria Drug Sales by Application (2021-2032) & (W Units)

7.1.2 Global Primary Hyperoxaluria Drug Sales Market Share by Application (2021-2032)

7.2 Global Primary Hyperoxaluria Drug Revenue by Application (2021-2032)

7.2.1 Global Primary Hyperoxaluria Drug Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 Primary Hyperoxaluria Drug Value Chain Analysis

8.1.1 Primary Hyperoxaluria Drug Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Primary Hyperoxaluria Drug Production Mode & Process

8.2 Primary Hyperoxaluria Drug Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Primary Hyperoxaluria Drug Distributors

8.2.3 Primary Hyperoxaluria Drug Customers

9 Global Primary Hyperoxaluria Drug Analyzing Market Dynamics

9.1 Primary Hyperoxaluria Drug Industry Trends

9.2 Primary Hyperoxaluria Drug Industry Drivers

9.3 Primary Hyperoxaluria Drug Industry Opportunities and Challenges

9.4 Primary Hyperoxaluria Drug Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Primary Hyperoxaluria Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Primary Hyperoxaluria Drug Sales (W Units) of Manufacturers (2021-2026)
- Table 7: Global Primary Hyperoxaluria Drug Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Primary Hyperoxaluria Drug Revenue of Manufacturers (2021-2026)
- Table 9: Global Primary Hyperoxaluria Drug Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Primary Hyperoxaluria Drug Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Primary Hyperoxaluria Drug Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Primary Hyperoxaluria Drug, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Primary Hyperoxaluria Drug, Product Type & Application
- Table 14: Global Primary Hyperoxaluria Drug Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Primary Hyperoxaluria Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: OxThera AB Company Information
- Table 19: OxThera AB Business Overview
- Table 20: OxThera AB Primary Hyperoxaluria Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: OxThera AB Primary Hyperoxaluria Drug Product Portfolio
- Table 22: OxThera AB Recent Developments
- Table 23: Intellia Therapeutics Inc Company Information
- Table 24: Intellia Therapeutics Inc Business Overview
- Table 25: Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Intellia Therapeutics Inc Primary Hyperoxaluria Drug Product Portfolio
- Table 27: Intellia Therapeutics Inc Recent Developments
- Table 28: Dicerna Pharmaceuticals Inc Company Information
- Table 29: Dicerna Pharmaceuticals Inc Business Overview
- Table 30: Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
- Table 32: Dicerna Pharmaceuticals Inc Recent Developments
- Table 33: Alnylam Pharmaceuticals Inc Company Information
- Table 34: Alnylam Pharmaceuticals Inc Business Overview
- Table 35: Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
- Table 37: Alnylam Pharmaceuticals Inc Recent Developments
- Table 38: Allena Pharmaceuticals Inc Company Information
- Table 39: Allena Pharmaceuticals Inc Business Overview
- Table 40: Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
- Table 42: Allena Pharmaceuticals Inc Recent Developments
- Table 43: Global Primary Hyperoxaluria Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 44: Global Primary Hyperoxaluria Drug Sales by Region (2021-2026) & (W Units)
- Table 45: Global Primary Hyperoxaluria Drug Sales Market Share by Region (2021-2026)
- Table 46: Global Primary Hyperoxaluria Drug Sales by Region (2027-2032) & (W Units)
- Table 47: Global Primary Hyperoxaluria Drug Sales Market Share by Region (2027-2032)
- Table 48: Global Primary Hyperoxaluria Drug Revenue by Region (2021-2026) & (US\$ Million)

- Table 49: Global Primary Hyperoxaluria Drug Revenue Market Share by Region (2021-2026)
- Table 50: Global Primary Hyperoxaluria Drug Revenue by Region (2027-2032) & (US\$ Million)
- Table 51: Global Primary Hyperoxaluria Drug Revenue Market Share by Region (2027-2032)
- Table 52: North America Primary Hyperoxaluria Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 53: North America Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units)
- Table 54: North America Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units)
- Table 55: North America Primary Hyperoxaluria Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 56: North America Primary Hyperoxaluria Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 57: Europe Primary Hyperoxaluria Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 58: Europe Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units)
- Table 59: Europe Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units)
- Table 60: Europe Primary Hyperoxaluria Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 61: Europe Primary Hyperoxaluria Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 62: Asia Pacific Primary Hyperoxaluria Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 63: Asia Pacific Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units)
- Table 64: Asia Pacific Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units)
- Table 65: Asia Pacific Primary Hyperoxaluria Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 66: Asia Pacific Primary Hyperoxaluria Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 67: South America Primary Hyperoxaluria Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 68: South America Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units)
- Table 69: South America Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units)
- Table 70: South America Primary Hyperoxaluria Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 71: South America Primary Hyperoxaluria Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 72: Middle East and Africa Primary Hyperoxaluria Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 73: Middle East and Africa Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units)
- Table 74: Middle East and Africa Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units)
- Table 75: Middle East and Africa Primary Hyperoxaluria Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 76: Middle East and Africa Primary Hyperoxaluria Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 77: Global Primary Hyperoxaluria Drug Sales by Type (2021-2026) & (W Units)
- Table 78: Global Primary Hyperoxaluria Drug Sales by Type (2027-2032) & (W Units)
- Table 79: Global Primary Hyperoxaluria Drug Sales Market Share by Type (2021-2026)
- Table 80: Global Primary Hyperoxaluria Drug Sales Market Share by Type (2027-2032)
- Table 81: Global Primary Hyperoxaluria Drug Revenue by Type (2021-2026) & (US\$ Million)
- Table 82: Global Primary Hyperoxaluria Drug Revenue by Type (2027-2032) & (US\$ Million)
- Table 83: Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2021-2026)
- Table 84: Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2027-2032)
- Table 85: Global Primary Hyperoxaluria Drug Price by Type (2021-2026) & (US\$/Unit)
- Table 86: Global Primary Hyperoxaluria Drug Price by Type (2027-2032) & (US\$/Unit)
- Table 87: Global Primary Hyperoxaluria Drug Sales by Application (2021-2026) & (W Units)
- Table 88: Global Primary Hyperoxaluria Drug Sales by Application (2027-2032) & (W Units)
- Table 89: Global Primary Hyperoxaluria Drug Sales Market Share by Application (2021-2026)
- Table 90: Global Primary Hyperoxaluria Drug Sales Market Share by Application (2027-2032)
- Table 91: Global Primary Hyperoxaluria Drug Revenue by Application (2021-2026) & (US\$ Million)
- Table 92: Global Primary Hyperoxaluria Drug Revenue by Application (2027-2032) & (US\$ Million)
- Table 93: Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2021-2026)
- Table 94: Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2027-2032)
- Table 95: Global Primary Hyperoxaluria Drug Price by Application (2021-2026) & (US\$/Unit)
- Table 96: Global Primary Hyperoxaluria Drug Price by Application (2027-2032) & (US\$/Unit)
- Table 97: Key Raw Materials
- Table 98: Raw Materials Key Suppliers
- Table 99: Primary Hyperoxaluria Drug Distributors List
- Table 100: Primary Hyperoxaluria Drug Customers List
- Table 101: Primary Hyperoxaluria Drug Industry Trends
- Table 102: Primary Hyperoxaluria Drug Industry Drivers
- Table 103: Primary Hyperoxaluria Drug Industry Restraints
- Table 104: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Primary Hyperoxaluria Drug Product Image
- Figure 5: Global Primary Hyperoxaluria Drug Revenue (US\$ Million), 2021 VS 2025 VS 2032

- Figure 6: Global Primary Hyperoxaluria Drug Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Primary Hyperoxaluria Drug Sales (2021-2032) & (W Units)
- Figure 8: Global Primary Hyperoxaluria Drug Average Price (US\$/Unit) & (2021-2032)
- Figure 9: ALLN-230 Product Image
- Figure 10: ALN-GO1 Product Image
- Figure 11: DCR-PHXC Product Image
- Figure 12: Others Product Image
- Figure 13: Hospital Product Image
- Figure 14: Clinic Product Image
- Figure 15: Others Product Image
- Figure 16: Global Primary Hyperoxaluria Drug Revenue Share by Manufacturers in 2025
- Figure 17: Global Manufacturers of Primary Hyperoxaluria Drug, Manufacturing Sites & Headquarters
- Figure 18: Global Top 5 and 10 Primary Hyperoxaluria Drug Players Market Share by Revenue in 2025
- Figure 19: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 20: Global Primary Hyperoxaluria Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 21: Global Primary Hyperoxaluria Drug Sales by Region in 2025
- Figure 22: Global Primary Hyperoxaluria Drug Revenue by Region in 2025
- Figure 23: North America Primary Hyperoxaluria Drug Market Size by Country in 2025
- Figure 24: North America Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2032)
- Figure 25: North America Primary Hyperoxaluria Drug Revenue Market Share by Country (2021-2032)
- Figure 26: United States Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Canada Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 28: Mexico Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 29: Europe Primary Hyperoxaluria Drug Market Size by Country in 2025
- Figure 30: Europe Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2032)
- Figure 31: Europe Primary Hyperoxaluria Drug Revenue Market Share by Country (2021-2032)
- Figure 32: Germany Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: France Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: U.K. Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Italy Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Russia Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Spain Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Netherlands Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Switzerland Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Sweden Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Poland Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Asia Pacific Primary Hyperoxaluria Drug Market Size by Country in 2025
- Figure 43: Asia Pacific Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2032)
- Figure 44: Asia Pacific Primary Hyperoxaluria Drug Revenue Market Share by Country (2021-2032)
- Figure 45: China Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: Japan Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: South Korea Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: India Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Australia Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Taiwan Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Southeast Asia Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Southeast Asia Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: South America Primary Hyperoxaluria Drug Market Size by Country in 2025
- Figure 54: South America Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2032)
- Figure 55: South America Primary Hyperoxaluria Drug Revenue Market Share by Country (2021-2032)
- Figure 56: Brazil Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Argentina Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Chile Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Middle East and Africa Primary Hyperoxaluria Drug Market Size by Country in 2025
- Figure 60: Middle East and Africa Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2032)
- Figure 61: Middle East and Africa Primary Hyperoxaluria Drug Revenue Market Share by Country (2021-2032)
- Figure 62: Egypt Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 63: South Africa Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: Israel Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Türkiye Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: GCC Countries Primary Hyperoxaluria Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: Global Primary Hyperoxaluria Drug Sales Market Share by Type (2021-2032)
- Figure 68: Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2021-2032)
- Figure 69: Global Primary Hyperoxaluria Drug Price (US\$/Unit) by Type (2021-2032)
- Figure 70: Global Primary Hyperoxaluria Drug Sales Market Share by Application (2021-2032)

- Figure 71: Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2021-2032)
- Figure 72: Global Primary Hyperoxaluria Drug Price (US\$/Unit) by Application (2021-2032)
- Figure 73: Primary Hyperoxaluria Drug Value Chain
- Figure 74: Primary Hyperoxaluria Drug Production Mode & Process
- Figure 75: Direct Comparison with Distribution Share
- Figure 76: Distributors Profiles
- Figure 77: Primary Hyperoxaluria Drug Industry Opportunities and Challenges